David R. Plowchalk - Concepedia

Author

David R. Plowchalk

Pfizer (United States)

Also Known As

D Plowchalk, D. Plowchalk, D. R. Plowchalk, David Plowchalk, David R. Plowchalk

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)University of Arkansas for Medical Sciences National Center for Toxicological Research DuPont (United States)Research Triangle Park Foundation

About

David R. Plowchalk is an author at Pfizer (United States) specializing in medicine, pharmacology, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	926
2	Public Health	5	5	392
3	Endocrinology	4	4	250
4	Health Sciences	2	2	137
5	Anesthesia	1	1	25

David R. Plowchalk

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction Odette A. Fahmi, Susan Hurst, David R. Plowchalk, Drug Metabolism and Disposition	2009	210
An EP2 receptor-selective prostaglandin E<sub>2</sub>agonist induces bone healing Vishwas Paralkar, Fran Borovečki, H.Z. Ke, Proceedings of the National Academy of Sciences Prostaglandin E2Molecular PhysiologySclerostinBone Morphogenic ProteinMedicine	2003	185
Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia Christie M. Ballantyne, Joel Neutel, Anne Cropp, The American Journal of Cardiology	2015	168
Phosphoramide mustard is responsible for the ovarian toxicity of cyclophosphamide David R. Plowchalk, Donald R. Mattison Toxicology and Applied Pharmacology MedicineGynecologyToxicologyFemale Reproductive FunctionPhosphoramide Mustard	1991	118
Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling Hannah M. Jones, Iain Gardner, Wendy T. Collard, Clinical Pharmacokinetics Physiologically Based PharmacokineticsPharmacokinetic ModellingPharmacodynamicsPharmacological StudyPhysiology	2011	111
Evaluation of Various Static In Vitro–In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug Md L T Vieira, Brian J. Kirby, Isabelle Ragueneau‐Majlessi, Clinical Pharmacology & Therapeutics	2013	101
Application of CYP3A4<i>in vitro</i>data to predict clinical drug–drug interactions; predictions of compounds as objects of interaction Kuresh Youdim, Aref Zayed, Maurice Dickins, British Journal of Clinical Pharmacology	2008	95
A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat David R. Plowchalk, Melvin E. Andersen, J.D. deBethizy Toxicology and Applied Pharmacology Tobacco ControlSubstance AbusePharmacokinetic ModelingHealth SciencesAddiction	1992	86
Reproductive toxicity of cyclophosphamide in the C57BL/6N mouse: 2. Effects on uterine structure and function David R. Plowchalk, M JANEMEADOWS, Donald R. Mattison Reproductive Toxicology FertilityReproductive ToxicityReproductive HealthFemale Reproductive SystemFemale Reproductive Function	1992	85
Reproductive toxicity of cyclophosphamide in the C57BL/6N mouse: 1. Effects on ovarian structure and function David R. Plowchalk, Donald R. Mattison Reproductive Toxicology Reproductive ToxicityOogenesisMedicineGynecologyFemale Reproductive System	1992	81

Page 1